Sustained CD8+ T-Cell Immune Response to a Novel Immunodominant HLA-B*0702-Associated Epitope Derived from an Epstein-Barr Virus Helicase-Primase-Associated Protein

Journal of Medical Virology

Volumn 72, Issue 4, 2004, Pages 635-645

  Turčanová, Vanda ^a   Höllsberg, Per ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Algorithms; Cytotoxic response; Peptide binding

Indexed keywords

BINDING PROTEIN; CD8 ANTIGEN; EPITOPE; HELICASE PRIMASE ASSOCIATED PROTEIN; HLA B7 ANTIGEN BINDING PEPTIDE; LPRA PEPTIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ALGORITHM; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; BBLF2 3 GENE; COMPUTER ANALYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; PREDICTION; SCORING SYSTEM; VACCINATION; VIRUS GENE; VIRUS GENOME; VIRUS INFECTION;

ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DNA HELICASES; DNA PRIMASE; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HLA-B ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; LIGANDS; LYMPHOCYTE ACTIVATION; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC;

HUMAN HERPESVIRUS 4;

EID: 1542304531     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20023     Document Type: Article

References (58)

1. Altuvia Y, Sette A, Sidney J, Southwood S, Margalit H. 1997. A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets. Hum Immunol 58:1-11.
2. Annels NE, Callan MF, Tan L, Rickinson AB. 2000. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. J Immunol 165:4831-4841.
3. Bharadwaj M, Moss DJ. 2002. Epstein-Barr virus vaccine: A cytotoxic T-cell-based approach. Exp Rev Vaccines 1:467-476.
4. + cytotoxic T lymphocytes following primary Epstein-Barr virus infection. Blood 98:2588-2589.
5. Bharadwaj M, Sherritt M, Khanna R, Moss DJ. 2001b. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: Implications for vaccine design. Vaccine 19:3769-3777.
6. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lindqvist C, Akerman K. 1996. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Methods 193:199-206.
7. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. 2002. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 3:627-634.
8. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 187:1395-1402.
9. Catalina MD, Sullivan JL, Bak KR, Luzuriaga K. 2001. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol 167:4450-4457.
10. + T cells in heterologous antiviral immunity and immunopathology in the lung. Nat Immunol 2:1067-1076.
11. Davenport MP, Fazou C, McMichael AJ, Callan MF. 2002. Clonal selection, clonal senescence, and clonal succession: The evolution of the T cell response to infection with a persistent virus. J Immunol 168:3309-3317.
12. Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, Bharadwaj M, Khanna R. 2003. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 101:3150-3156.
13. Engelhard VH. 1994. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 12:181-207.
14. Falk K, Rotzschke O, Deres K, Metzger J, Jung G, Rammensee HG. 1991a. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med 174:425-434.
15. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. 1991b. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296.
16. Fixman ED, Hayward GS, Hayward SD. 1995. Replication of Epstein-Barr virus oriLyt: Lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol 69:2998-3006.
17. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. 2000. Multiple sclerosis: A modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 55:140-148.
18. Fujii K, Yokoyama N, Kiyono T, Kuzushima K, Homma M, Nishiyama Y, Fujita M, Tsurumi T. 2000. The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex. J Virol 74:2550-2557.
19. Gao Z, Krithivas A, Finan JE, Semmes OJ, Zhou S, Wang Y, Hayward SD. 1998. The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J Virol 72:8559-8567.
20. Hill A, Worth A, Elliott T, Rowland-Jones S, Brooks J, Rickinson A, McMichael A. 1995. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. Eur J Immunol 25:18-24.
21. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. 2002. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 195:893-905.
22. + T-cell responses against Epstein-Barr virus. Scand J Immunol 55:189-195.
23. Hollsberg P, Wucherpfennig KW, Ausubel LJ, Calvo V, Bierer BE, Hafler DA. 1992. Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. J Immunol 148:3256-3263.
24. Huczko EL, Bodnar WM, Benjamin D, Sakaguchi K, Zhu NZ, Shabanowitz J, Henderson RA, Appella E, Hunt DF, Engelhard VH. 1993. Characteristics of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling. J Immunol 151:2572-2587.
25. Khanna R, Burrows SR. 2000. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 54:19-48.
26. Khanna R, Moss DJ, Burrows SR. 1999a. Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 170:49-64.
27. Khanna R, Sherritt M, Burrows SR. 1999b. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 162:3063-3069.
28. Kim SK, Brehm MA, Welsh RM, Selin LK. 2002. Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. J Immunol 169:90-98.
29. Klenerman P, Zinkernagel RM. 1998. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394:482-485.
30. Le TT, Drane D, Malliaros J, Cox JC, Rothel L, Pearse M, Woodberry T, Gardner J, Suhrbier A. 2001. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine 19:4669-4675.
31. + T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 62:6952-6958.
32. Liu XS, Xu Y, Hardy L, Khammanivong V, Zhao W, Fernando GJ, Leggatt GR, Frazer IH. 2003. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol 171:4765-4772.
33. Lu J, Celis E. 2000. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res 60:5223-5227.
34. Moss DJ, Burrows SR, Silins SL, Misko I, Khanna R. 2001. The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci 356:475-488.
35. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, Salio M, Van Pel A, Man S, Bonin E, Liljestrom P, Dunbar PR, Cerundolo V. 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168:4391-4398.
36. Parker KC, Bednarek MA, Coligan JE. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175.
37. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. 1999. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50:213-219.
38. Rickinson AB, Kieff E. 2001. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins. pp 2575-2627.
39. Rickinson AB, Moss DJ. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15:405-431.
40. Rickinson AB, Callan MF, Annels NE. 2000. T-cell memory: Lessons from Epstein-Barr virus infection in man. Philos Trans R Soc Lond B Biol Sci 355:391-400.
41. Retzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG. 1991. Exact prediction of a natural T cell epitope. Eur J Immunol 21:2891-2894.
42. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E. 1990. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64:4084-4092.
43. Schirle M, Weinschenk T, Stevanovic S. 2001. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J Immunol Methods 257:1-16.
44. Selin LK, Lin MY, Kraemer KA, Pardoll DM, Schneck JP, Varga SM, Santolucito PA, Pinto AK, Welsh RM. 1999. Attrition of T cell memory: Selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 11:733-742.
45. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586-5592.
46. + cytotoxic T lymphocytes during primary and persistent infection. Int Immunol 9:1745-1755.
47. Silins SL, Sherritt MA, Silleri JM, Cross SM, Elliott SL, Bharadwaj M, Le TT, Morrison LE, Khanna R, Moss DJ, Suhrbier A, Misko IS. 2001. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 98:3739-3744.
48. Smith MH, Lam KS, Hersh EM, Lebl M, Grimes WJ. 1994. Peptide sequences binding to MHC class I proteins. Mol Immunol 31:1431-1437.
49. Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB. 1996. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 184:1801-1813.
50. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185:1605-1617.
51. Sun Q, Burton R, Reddy V, Lucas KG. 2002. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 118:799-808.
52. + T cells specific for EBV in healthy virus carriers. J Immunol 162:1827-1835.
53. + cytotoxic T cells: Implications for vaccine design. Proc Natl Acad Sci USA 92:5845-5849.
54. Thomson SA, Elliott SL, Sherritt MA, Sproat KW, Coupar BE, Scalzo AA, Forbes CA, Ladhams AM, Mo XY, Tripp RA, Doherty PC, Moss DJ, Suhrbier A. 1996. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 157:822-826.
55. Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A. 1998. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 160:1717-1723.
56. van der Burg SH, Ras E, Drijfhout JW, Benckhuijsen WE, Bremers AJ, Melief CJ, Kast WM. 1995. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol 44:189-198.
57. Voorter CE, van der Vlies SA, van den Berg-Loonen EM. 2000. Sequence-based typing of HLA-B: The B7 cross-reacting group. Tissue Antigens 56:356-362.
58. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. 2001. Cross-reactivity between hepatitis C virus and influenza A virus determinant-specific cytotoxic T cells. J Virol 75:11392-11400.